Latest From NuVasive Inc.
Reported sales and earnings from the big publicly traded orthopedics device companies showed mostly slow growth in 2018, but NuVasive and Stryker reported high single-digit growth while, Smith & Nephew grew in the low single-digits, fueling reports that Smith & Nephew may try to buy NuVasive.
Medtech continues to outperform biotech from a sustainable investment growth point of view, and meanwhile medtech CEOs are on message about advancing value- and outcomes-based models with their provider partners. It all points to medtech being in a good place for 2019, and there is no reason for M&A and industry consolidation to stop anytime soon, says Jefferies equity analyst Raj Denhoy.
Reported sales and earnings from the publicly traded orthopedics device companies showed mix results during the third quarter of 2018. NuVasive was the star performer in the group while, on the other end of the spectrum, Stryker continued to show strong growth across most its businesses, while Johnson & Johnson's orthopedic device revenue was near flat.</p>
About three years after becoming CEO of NuVasive, Gregory Lucier is ceding the role to Barry, who has led Medtronic's Surgical Innovations business, effective Nov. 5. Lucier will continue to serve as chairman of the board for the San Diego-based minimally-invasive spine surgery technology company.
- Implantable Devices
- Monitoring Equipment & Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- North America
- Parent & Subsidiaries
- NuVasive Inc.
- Senior Management
Christopher J Barry, CEO
Rajesh J Asarpota, EVP, CFO
Matt Link, Pres.
- Contact Info
Phone: (858) 909-1800
7475 Lusk Blvd.
San Diego, CA 92121
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.